EP2897528A1 - Fluid sampling apparatus and method - Google Patents
Fluid sampling apparatus and methodInfo
- Publication number
- EP2897528A1 EP2897528A1 EP13770962.2A EP13770962A EP2897528A1 EP 2897528 A1 EP2897528 A1 EP 2897528A1 EP 13770962 A EP13770962 A EP 13770962A EP 2897528 A1 EP2897528 A1 EP 2897528A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- fluid
- sampling apparatus
- samples
- elongate tube
- discrete
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150992—Blood sampling from a fluid line external to a patient, such as a catheter line, combined with an infusion line; Blood sampling from indwelling needle sets, e.g. sealable ports, luer couplings or valves
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/02—Devices for withdrawing samples
- G01N1/10—Devices for withdrawing samples in the liquid or fluent state
- G01N1/18—Devices for withdrawing samples in the liquid or fluent state with provision for splitting samples into portions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14525—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using microdialysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14525—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using microdialysis
- A61B5/14528—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using microdialysis invasively
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150053—Details for enhanced collection of blood or interstitial fluid at the sample site, e.g. by applying compression, heat, vibration, ultrasound, suction or vacuum to tissue; for reduction of pain or discomfort; Skin piercing elements, e.g. blades, needles, lancets or canulas, with adjustable piercing speed
- A61B5/150061—Means for enhancing collection
- A61B5/150099—Means for enhancing collection by negative pressure, other than vacuum extraction into a syringe by pulling on the piston rod or into pre-evacuated tubes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150206—Construction or design features not otherwise provided for; manufacturing or production; packages; sterilisation of piercing element, piercing device or sampling device
- A61B5/150221—Valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150206—Construction or design features not otherwise provided for; manufacturing or production; packages; sterilisation of piercing element, piercing device or sampling device
- A61B5/150229—Pumps for assisting the blood sampling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150755—Blood sample preparation for further analysis, e.g. by separating blood components or by mixing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/155—Devices specially adapted for continuous or multiple sampling, e.g. at predetermined intervals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/157—Devices characterised by integrated means for measuring characteristics of blood
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/505—Flexible containers without fluid transport within
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2560/00—Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
- A61B2560/02—Operational features
- A61B2560/0242—Operational features adapted to measure environmental factors, e.g. temperature, pollution
- A61B2560/0247—Operational features adapted to measure environmental factors, e.g. temperature, pollution for compensation or correction of the measured physiological value
- A61B2560/0257—Operational features adapted to measure environmental factors, e.g. temperature, pollution for compensation or correction of the measured physiological value using atmospheric pressure
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/06—Fluid handling related problems
- B01L2200/0673—Handling of plugs of fluid surrounded by immiscible fluid
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/14—Process control and prevention of errors
- B01L2200/143—Quality control, feedback systems
- B01L2200/146—Employing pressure sensors
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0832—Geometry, shape and general structure cylindrical, tube shaped
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/14—Means for pressure control
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0475—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure
- B01L2400/0481—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure squeezing of channels or chambers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/06—Valves, specific forms thereof
- B01L2400/0605—Valves, specific forms thereof check valves
Definitions
- Microdialysis is a well-established, common clinical and experimental procedure and involves insertion of a narrow bore sterile probe, with a semi -perm cable membrane of a certain length and character, into a body compartment of interest, such as subcutaneous tissue or within the venous compartment. An isotonic fluid is passed through the probe and biological substances of interest pass into this fluid for subsequent analysis. Effluent dialysate emerges as a continuous flow and has to be collected manually, or via large bench-top fraction collectors, into individually marked containers.
- HPA hypothalamic-pituitary-adrenal
- the diumal rhythm is often inferred from two, or a few isolated time-point measurements in the blood or saliva (Nieman L et al J Clin Endocrinol Metab 2008 93 1526- 1540), while often, pharmacological manipulation has to be employed to interrogate the HPA axis (Nieman L et iiidocrinol Metab 2008 93 1526-1540, Burk et al. Psychoneuroendo 2005 30(9) 846-865). Considering the nature of diurnal and ultradian variation, single or only a few measurements are inadequate. Summary
- a fluid sampling apparatus comprising:
- a fluid partitioning unit comprising:
- a first port arranged to receive an incoming flow of test fluid; and a second port arranged to be coupled to the elongate tube,
- the fluid partitioning unit is arranged to combine the flow of test fluid with a plurality of partitioning elements to define a plurality of discrete temporally organised fluid samples for movement along and storage within the elongate tube.
- the apparatus provides a simple means of continuous fluid sampling, in contrast to the known container-based approach.
- the plurality of discrete fluid samples may be moved into the tube and, once a required quantity are within the tube, the driving force causing the fluid samples to move may be removed such that the fluid samples within the tube may remain stored within the tube.
- the apparatus may therefore enable uninterrupted fluid sampling over a long period of time, which is advantageous in comparison to a subject, such as a human, being connected to a bench-top collecting apparatus that limits mobility and is an abnormal constraint on normal activities.
- a clinical facility necessary for known bodily fluid sampling methods may introduce an element of artificial stress as it is an environment alien to the individual.
- the apparatus and method of the present invention allow multiple discrete samples of bodily fluid to be obtained from a subject, such as a human, undergoing a normal pattern of 24 hour activity in their own home/work environment without pain, stress, blood loss or physical inconvenience to the subject, including nocturnal collection during sleep.
- a subject such as a human
- This may be particularly advantageous when the fluid sampling apparatus is sampling a test fluid containing Cortisol or the like, which can be affected by the human's response to the sampling.
- ite tube and /or partitioning elements may be arranged to maintain the structure of the plurality of discrete fluid samples within the tube.
- the elongate tube and /or paititioning elements are arranged to maintain the structure of the plurality of discrete fluid samples within the tube while the ends of the tube are open to atmosphere.
- the elongate tube and /or partitioning elements are arranged to maintain the structure of the plurality of discrete fluid samples within the tube when at least one end of the elongate tube is closed in a substantially fluid-tight manner; for example, by a cap.
- the bore of the tube may be circular, or any other suitable shape.
- the elongate tube may be used to store, transport etc. collected fluid samples.
- the test fluid may comprise a liquid.
- the fluid partitioning unit may be arranged to introduce the partitioning elements in succession into the flow of test fluid.
- test fluid may be an uninterrupted flow, in contrast with apparatus in which a test fluid is periodically injected into a carrier fluid.
- the fluid partitioning unit is arranged to introduce the partitioning elements in succession into the flow of test fluid may widen the possible sources of test fluid to include fluids such as bodily fluid.
- the partitioning elements may comprise globules of a second fluid which is immiscible with respect to the test fluid.
- the second fluid may comprise a liquid, or a gas that is non-reactive and/or insoluble with respect to the test fluid.
- the partitioning eiements may be formed from a substance that is simple to manipulate in comparison to a solid partitioning element.
- the elongate tube may be arranged to store a sufficient quantity of discrete fluid samples to enable uninterrupted sampling at a flow rate of at least 1 uL/min for at least four hours, eight hours, ten hours, twelve hours, preferably at least twenty four hours and in some cases at least seventy two hours; for example, the length of the tube may be selected to match the required volume of fluid samples and partitioning elements.
- sampling apparatus may include a control pump operable to force the plurality of discrete fluid samples towards the elongate tube.
- the apparatus can bias the discrete fluid samples into the tube, which enables use of the apparatus in situations where the pressure required to move the column of discrete fluid samples further into the tube is greater than the pressure of incoming test fluid.
- the fluid sampling apparatus may include a pressure sensor arranged to measure fluid pressure within the first port and a control circuit arranged to monitor the pressure difference between the fluid within the first port and a reference pressure and generate a control signal operable to modify the operation of the control pump accordingly.
- the fluid sampling apparatus may include a pressure sensor arranged to measure local atmospheric pressure outside of the fluid sampling apparatus and wherein the reference pressure comprises the measured local atmospheric pressure.
- the apparatus can control operation of the pump to ensure that the fluid pressure at the first port is substantially constant, which can be desirable in applications such as when the first port is coupled to a medical or veterinary device, or other device suitable for pumping test fluid into the fluid sampling apparatus at a controlled flow rate.
- the elongate tube may be arranged to retain the plurality of discrete fluid samples when uncoupled from the fluid partitioning unit.
- the elongate tube may be arranged in a coiled configuration. This may be achieved by a bracket or strap which maintains the coiled arrangement.
- the elongate tube may be arranged in a compact configuration that lends itself to portability.
- the fluid sampling apparatus may be arranged such that each discreet fluid sample is longer than it is wide. lay be formed of a material liaving one or more of the following properties:
- a fluidphobic material such as a hydrophobic material
- the first port of the partitioning unit may be arranged to be coupled to, or in combination with, a medical device, such as a microdialysis device.
- the apparatus may provide a solution to the problem of how to obtain a full 24 hour profile of hormones that are known to cycle both on a daily (diurnal) and near hourly (ultradian) fashion. This can be very important as abnormalities are often the most clinically- relevant during the time of the hormonal nadir when hormone levels are at their lowest. This time is - for Cortisol - between midnight and 3.00 am - times at which routine sampling techniques are difficult, hi some embodiments the apparatus may be arranged to sample a test fluid containing prescription drugs or experimental drugs, which may be useful in clinical trials or monitoring drug therapy. In some embodiments the apparatus may be arranged to sample a test fluid containing drug metabolites and/or other suitable biomarkers for clinical trials.
- the components of the apparatus may be selected to have a total mass of less or equal to 20kg, and preferably less than or equal to 1kg.
- the fluid partitioning unit may be encapsulated within a housing arranged to be comfortable for a user to wear, and non- intrusive.
- the apparatus may be portable and wearable for a long period of time, enabling fluid sampling from a human or other animal body over a prolonged period.
- a test fluid comprising the steps of:
- the steps of combining and delivering may continue for at least twenty four hours.
- the partitioning elements may be combined with the test fluid at a frequency of at least 1 per hour so that the discrete fluid samples are partitioned into time dependent increments.
- the test fluid may comprise one or more substances of interest such as proteins, steroids, drugs or other chemical compounds.
- a substance of interest may be a hormone, preferably a hormone which shows circadian variability such as a diurnal and/or ultradian rhythm.
- Hormones of interest may include gonadotrophin-releasing hormone (GnRH), luteinizing hormone (LH), follicle stimulating hormone (FSH), prolactin, testosterone, growth hormone, melatonin, thyroid stimulating hormone (TSH), insulin, parathyroid hormone (PTH), adrenocortocotrophic hormone (ACTH) and Cortisol.
- the hormone is Cortisol, growth hormone or insulin.
- the substances of interest may include catecholamines such as epinephrine (adrenaline), norepinephrine (noradrenaline) and dopamine.
- Other substances of interest may include lactic acid and glucose.
- the substance of interest may include a drug or metabolite.
- an elongate tube arranged or specially adapted for use with apparatus according to the first aspect and/or use in a method according to the second aspect.
- the method may further comprise separating the plurality of discrete fluid samples from one another and analysing the samples for the one or more substances of interest.
- Figure 1 is a diagram of fluid sampling apparatus according to an embodiment of the invention
- Figure 2 is a diagram of fluid sampling apparatus according to a further embodiment of the invention
- Figure 3 is a diagram of fluid sampling apparatus according to a yet further embodiment of the invention, wherein the apparatus is arranged to be coupled to microdialysis device.
- Figure 4 shows circuit diagrams for a pressure servo and a bubble timer of specific embodiments of the invention.
- Figure 5 shows two individual 24 hour profiles of human subcutaneous tissue free Cortisol measured from samples collected using the apparatus of the present invention.
- Figure 1 shows fluid sampling apparatus 10 according to an embodiment of the invention.
- the fluid sampling apparatus 10 has a fluid partitioning unit 12 arranged to receive a flow of test fluid TF and partition it into a plurality of individual fluid samples FS, and an elongate tube 14 arranged to store the plurality of individual fluid samples FS.
- the fluid partitioning unit 12 defines a fluid passage 16 having a first port 18 and a second port 20.
- the first port 18 is arranged to be coupled to a source of test fluid (not shown) to define a substantially fluid-tight passageway between the fluid partitioning unit 12 and the source of test fluid to receive the flow of test fluid TF.
- the test fluid TF is a fluid that contains a substance of interest and as such is to be sampled.
- the test fluid TF may be a liquid or a gas.
- the test fluid TF is a bodily fluid, such as blood or cerebrospinal fluid. Where the test fluid TF is blood, anticoagulation fluid should be added.
- the test fluid TF is microdiaiysate.
- the second port 20 is arranged to be coupled to the elongate tube 14 to define a substantially fluid-tight passageway between the fluid partitioning unit 12 and the elongate tube 14.
- the first port 18 and second port 20 may define any suitable connection type, such as a sleeve or collar sized to form an interference fit with a resiliently deformable tube.
- the first port 18 and/or second port 20 may define a Luer or Luer Lock fitting.
- a partitioning element insertion unit 22 is coupled to the fluid passage 16 via a third port 24 located between the first port 18 and second port 20, The partitioning element insertion unit 22 is arranged to insert partitioning elements 26 into the flow of test fluid TF to create a plurality of discreet fluid samples FS that are delivered to the elongate tube 14 via the second port 20.
- the fluid partitioning unit is arranged to introduce the partitioning elements 22 in succession into the flow of test fluid TF.
- partitioning elements 22 may be introduced with 1.25, 2.5, 5, 10, 20, 30 or 60 minutely frequency, although any- suitable and/or desirable frequency may be used.
- the discrete fluid samples may be taken at intervals of from about 1 minute to 4 hours, in some embodiments from about I minute to about I hour, preferably from about 1 minute to about 20 minutes, most preferably about 10 minutes. In some embodiments it is desirable for the fluid samples to be taken at intervals of from about 10 minutes to 1 hour.
- the partitioning elements 26 may take any suitable form that effectively partitions the test fluid TF and can be moved along the elongate tube 14.
- the partitioning elements 26 may be globules or bubbles of a fluid that is generally immiscible with respect to the test fluid TF.
- the second fluid may comprise a gas that is non-reactive and/or insoluble with respect to the test fluid TF.
- the second fluid is an inert gas, such as nitrogen or argon.
- the second fluid is air.
- the partitioning elements 26 may be solid objects sized to match the inner diameter of the elongate tube 14, although a fluid is preferred for the partitioning elements 26 because a fluid partitioning element may conform better to the inner diameter of the elongate tube 14, may be lighter than a solid partitioning element and may be simpler to manipulate into the stream of test fluid TF.
- the elongate tube 14 is arranged to store the plurality of discreet fluid samples FS.
- the distal opening 28 of elongate tube 14 with respect to the opening coupled to the second port 20 is open to the atmosphere so as to allow air A within the elongate tube 14 to egress as the plurality of discreet fluid samples FS are moved into the tube 14 for storage.
- the fluid sampling apparatus 10 is arranged to maintain the structure of plurality of individual fluid samples FS such that the fluid samples do not mix with one another.
- the fluid sampling apparatus 10 may be arranged to dispense partitioning elements 26 into test fluid TF of a particular flow rate such that each discreet fluid sample is longer than it is wide. This may promote stability of each individual fluid sample, which is advantageous in embodiments where the partitioning elements 26 are in the form of a fluid.
- the length of a fluid sample may refer to its axial dimension, whereas its width may refer to the internal diameter of the tube 14.
- the elongate tube 14 may be formed of a fluidphobic material having a low degree of wetting with respect to the test fluid.
- 'wetting' is a measure of a liquid's ability to maintain contact with a solid surface due to intermolecular interactions when the liquid and solid are brought together.
- the degree of wetting is determined by a force balance between adhesive and cohesive forces.
- the fluid within the elongate tube 14 is more inclined to remain in a globule than it is to flatten and mix with an adjacent globule.
- a high surface tension increases the force needed to move fluid partitioning elements 26 along the elongate tube 14.
- the elongate tube 14 may therefore be formed of a hydrophobic material. Suitable materials include perfluoroalkoxy (PFA) and fluorinated ethylene propylene (FEP), in a preferred embodiment of the invention the elongate tube is formed of polytetrafluoroethylene (PTFE).
- PFA perfluoroalkoxy
- FEP fluorinated ethylene propylene
- the elongate tube is formed of polytetrafluoroethylene (PTFE).
- the partitioning elements 26 are formed of a liquid that is generally immiscible with respect to the test fluid TF
- the elongate tube 14 it may be advantageous for the elongate tube 14 to be formed of an oleophobie material that preferably also exhibits a low degree of wetting with respect to the test fluid.
- the material is inert and has a low binding affinity for proteins.
- the resistance to droplet motion, due to surface tension, will decrease with a decrease in tube diameter. If the tube diameter is reduced by a factor of 2, say, then the force will reduce by a factor of 2. However, the cross-sectional area of the tube will reduce by a factor of 4, so that pressure will need to increase by a factor of 2 to overcome the resistance. In some embodiments, particularly those where it is important for the apparatus to be portable or usable for long periods of time without interruption, this may have implications for the internal cross-sectional area of the elongate tube 14; for example, the tube 14 may be sized to avoid a high pressure build up within the elongate tube 14.
- the flow rate of test fluid TF may be from about 0.01 to about 50 uL/min, preferably about 0.1 to about 10 ⁇ / ⁇ , more preferably about 0.1 to about 5 uL/min. In a preferred embodiment of the invention the flow rate is about 2 ulViriin.
- the device of the present invention may be used for uninterrupted sampling over a period of about 1 hour to about 72 hours, preferably about 12 hours to about 48 hours, most preferably about 24 hours.
- the elongate tube 14 is arranged to store a sufficient quantity of discrete fluid samples to enable uninterrupted sampling at a flow rate of at least 1 uL/min for at least twenty four hours.
- the elongate tube 14 is has an internal diameter sized to inhibit mixing between the plurality of discreet fluid samples FS through fluid partitioning elements 26; for example, the tube 14 may have an internal diameter of lmm and the apparatus 10 controlled such that the fluid samples each have a size of 20uL, which gives a sample length of approx. 25mm. For 144 samples (24hrs at lOmin) this may give rise to 0.3 to 0.5 atmosphere pressure to move the column of fluid samples along the tube 14. If the tube 14 diameter is halved the pressure may double, meaning that the pump or pumps driving the test fluid TF and/or plurality of discreet fluid samples FS would be under greater stress and connectors may need to be enhanced to inhibit leakage.
- the plurality of discreet fluid samples FS may each be about 6mm long and 2mm in diameter.
- the skilled person will see from this that there is a complex relationship between tube diameter, sample interval, flow rate and duration and, due to this, applications may have to be assessed individually.
- the plurality of discreet fluid samples FS may each have a width that is greater than their length, which may provide an unstable configuration with fluid partitioning elements 26, so in such case s solid partitioning elements 26 should be used.
- elongate tubes may be used.
- _ lie tube 14 may advantageously be arranged in a coiled configuration. This may be achieved by a bracket or strap which maintains the coiled arrangement, or the tube may be wound around a spool. Such configurations advantageously reduce the envelope of the elongate tube.
- the fluid sampling apparatus 10 may be coupled to a source of test fluid TF.
- the fluid partitioning unit 12 combines the flow of test fluid TF with the partitioning elements 26 to partition the flow of test fluid TF into a plurality of discrete fluid samples FS which are delivered to the elongate tube 14 for storage. Once a predetermined number of discrete fluid samples FS have been moved into the elongate tube 14, the elongate tube can be uncoupled from the fluid partitioning unit 12 for analysis.
- the elongate tube 14 is arranged to retain the plurality of discrete fluid samples FS when uncoupled from the fluid partitioning unit; for example, the internal diameter may be sized such that the pressure required to move the plurality of discrete fluid samples FS along the tube is greater than the pressure exerted due to gravity, in other embodiments, an end cap or other covering means (not shown) may be provided to close one or both ends of the elongate tube 14 to inhibit egress of the plurality of discrete fluid samples FS following uncoupling of the elongate tube 14 from the fluid partitioning unit 12.
- the distal opening 28 of the elongate tube 14 may be provided with a one way valve to permit air to egress from the elongate tube 14, but inhibit fluid entering.
- the components of the apparatus 10 may be selected to have a total mass of less or equal to 20kg, and preferably less than or equal to 1kg.
- the fluid partitioning unit 12 may be encapsulated within a housing arranged to be comfortable for a user to wear, an non- intrusive.
- the apparatus 10 may be portable and wearable for a long period of time, enabling fluid sampling from a human body over a prolonged period.
- Figure 2 shows fluid sampling apparatus 30 according to a further embodiment of the invention.
- the fluid sampling apparatus 30 of the illustrated embodiment is similar- to that shown in Figure 1 and like parts have been given the same reference numerals.
- the fluid sampling apparatus 30 of the illustrated embodiment additionally includes a pressure modifying assembly 34 arranged monitor the pressure difference between the fluid first port 18 and a reference pressure and generate a control signal operable to modify the operation of a control pump 40 ensure that the fluid pressure at the first port is substantially constant, which can be desirable in applications where it is undesirable to let the pressure at the first port increase, which can occur as the plurality of discreet fluid samples FS are moved into the elongate tube 14.
- a pressure modifying assembly 34 arranged monitor the pressure difference between the fluid first port 18 and a reference pressure and generate a control signal operable to modify the operation of a control pump 40 ensure that the fluid pressure at the first port is substantially constant, which can be desirable in applications where it is undesirable to let the pressure at the first port increase, which can occur as the plurality of discreet fluid samples FS are moved into the elongate tube 14.
- the pressure modifying assembly 34 includes a pressure sensor 36 arranged to measure fluid pressure within the first port 18 and a control circuit 38 arranged to monitor the pressure difference between the fluid within the first port 18 and a reference pressure, and generate a control signal operable to modify the operation of the control pump 40 accordingly.
- the reference pressure may be local atmospheric pressure, measured by an appropriate pressure sensor.
- the control circuit 38 may also be arranged to control the introduction of the partitioning elements 26 into the flow of test fluid TF. Any suitable conventional pressure sensor 36 may be used, such as a Honeywell 26 PC A F A 60.
- Any suitable conventional control pump 40 may be used; for example, a peristaltic pump such as a Dolomite Peristaltic Pump Part no. 3200243.
- the power consumption of the fluid sampling apparatus is low enough to utilise battery power for prolonged periods and in such cases low voltage electronic circuits, such as a maximum of 3 volts, may be provided.
- a low voltage circuit and/or a fuse may also increase user safety.
- the fluid sampling apparatus 30 works in a similar manner to the apparatus 10 of Figure 1.
- the apparatus of the illustrated embodiment additionally measures the fluid pressure within the apparatus 30 and compares the measured pressure to a reference pressure. If the two pressure values differ by more than a predetermined amount, or in some cases if a particular one exceeds the other, the pump 40 is operated to modify the pressure at the location of measurement such that the measured pressure becomes closer to the reference pressure.
- the fluid sampling apparatus 30 according to the illustrated embodiment may be used in situations where the incoming test TF is sensitive to fluid pressure variations; for example, in microdialvsis, or other applications such as blood or cerebrospinal fluid sampling.
- FIG 3 shows fluid sampling apparatus 50 according to a further embodiment of the invention.
- the fluid sampling apparatus 50 of the illustrated embodiment is similar to that shown in Figure 2 in that the sampling apparatus 50 has a fluid partitioning unit 52 arranged to receive a flow of test fluid TF and partition it into a plurality of individual fluid samples FS, it has pump means 40 to control the fluid pressure, and an elongate tube 14 arranged to store the plurality of individual fluid samples FS; like parts have been given the same reference numerals.
- the fluid sampling apparatus 50 of the illustrated embodiment is arranged to be coupled to microdialvsis device 60.
- An isotonic fluid is passed through the probe 64 and biological substances of interest pass into this fluid for subsequent analysis.
- the effluent dialysate emerges as a continuous flow.
- the microdialysis device 60 is coupled to the first port 18 via a connector 66, which is shown as being part of the microdialysis device 60 but in practice may be an external connector used to connect the microdialysis device 60 to the fluid partitioning unit 52.
- the power consumption of the fluid sampling apparatus 50 is low enough to allow us to utilise battery power only, for prolonged periods.
- microdialysis (Cohen Crit Care 2009).
- a microdialysis pump 62 (CMA 107 microdialysis pump, Sweden) was used to infuse an ilution through a microdialysis probe 64 inserted subcutaneously into the anterior abdominal wall. Isotonic fluid was infused through the probe at the rate of 2 microlitres/ minute .
- the microdialysate was then collected in our automated fluid sampling apparatus 50, the collected samples being stored in a length of polytetrafluoroethylene (PTFE) tubing 14, wrapped concentrically around a spool .
- PTFE polytetrafluoroethylene
- the division of samples generated at different times was achieved by the injection of an air bubble at predetermined intervals.
- the bubbles separate individual samples which then move along the tubing 14 as new samples are introduced.
- the pump 22b was advantageously small in size, light weight and used low current consumption.
- a Dolomite Peristaltic Pump Part no. 3200243 was chosen.
- the senor 36 had semi-conductor piezo resistive elements in a Wheatstone bridge arrangement.
- the output from the bridge was fed into a high gain differential stage using U1A.
- RV1 was used to offset any bridge output present when the pressure is zero.
- the servo pump motor was driven from, the pressure signal using pulse width modulation. This was necessary to maintain a high torque at low miming speeds.
- the op-amp U2B is an oscillator which generated an approximately triangular waveform across CI. This signal was fed into the -ve input of U2A, which was used as a comparator. The +ve input was fed with re signal after adding a preset DC level using op-amp U1B as a unity gain differential amplifier. The output from the comparator was fed into transistor Ql which switched the current to the servo motor between full current and zero. As the pressure increased the full current dwell time increased driving the motor harder and thus reducing the pressure. RV2 set the probe line pressure by determining the point where the motor starts to get driven. This servo system kept the pressure constant to within about 10 cm of water pressure.
- the frequency of sampling was determined by the periodiaty of the bubbles inserted in the micrdodialysate column by the U3 complementary metal-oxide semiconductor (CMOS) 555 timer. This ran as an astable multivibrator to give a clock frequency of 13.65Hz, pre-set using RV3.
- This clock signal was fed to U4 which is a type 4020 multi stage binary divider.
- the output from stage 12 had a period of 10 minutes and triggered U5.
- This was another CMOS 555 timer this time running in monostable mode generating a pulse of around two seconds duration, pre-set by RV4.
- This pulse turned on transistor Q2 which powered motor for the air bubble insertion pump.
- the dimensions of the final collection system were 152 mm x 84 mm x 52 mm (length x breadth x height respectively), and the weight was 400 grams.
- the inner components of the compact device which is made of plastic, were accessible through its removable lid. Put another way, the components of the fluid sampling apparatus are encapsulated in a casing having a removable lid. Access to the device enables replacement of batteries and PTFE tubing.
- the distal end of a linear microdiaiysis probe was connected to the collection system using a 15-20 cm section of fluorinated ethylene propylene (FEP) tubing and a commercially available connector 66.
- FEP fluorinated ethylene propylene
- the most convenient site of insertion for the microdiaiysis probe was the lower abdominal wall. pling was complete, individual samples were decanted manually into marked tubes and stored for laboratory analysis.
- Microdialysis fluid from each timed sample was pipetted into an individual well of a 96 well plate and free Cortisol measured using enzyme-linked immunosorbent assay (Saliva Cortisol ELISA, IBL, Germany).
- the sensitivity of our assay was 0.005Lig/dL with inter- and intra- assay coefficients of variation of 9.3% ⁇ and 4.2% respectively.
- Two typical individual 24 hour profiles of subcutaneous tissue free Cortisol are seen in Figure 5.
- the fluid sampling apparatus 50 may have one or more of the following advantages:
- Miniaturized portable sample collection device the dimensions of the collection system are 152 mm. x 84 mm x 52 mm (length x breadth x height respectively), and the weight is 400 grams. It fits comfortably, along with the microdialysis pump, within a commercial waistbag routinely available for travel purposes. disturbed nocturnal sample collection during sleep - the device makes sample collection possible without an individual's knowledge, safely in their own environment, without causing any pain or discomfort. In some cases the individual may be completely- unaware of the sampling process taking place in the background. Therefore, samples can be collected continuously throughout the night when an individual is asleep. This is a particularly advantageous feature of the device.
- the apparatus enables continuous, un- interfered sampling of microdialysate samples throughout sleep in an individual's home, without the need to attend a clinical facility.
- Automated sample collection - despite technological advances of great significance in the twenty first century with numerous instances of automation in various walks of life, application of the knowledge in the field of continuous prolonged biosampling has been lacking.
- Discrete timed sample collection and storage the apparatus 50 has the ability to provide the approximate time of each sample fraction contained within the collection spool defining the elongate tube, due to the temporal organisation of the samples.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Optics & Photonics (AREA)
- Manufacturing & Machinery (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Clinical Laboratory Science (AREA)
- Hydrology & Water Resources (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Sampling And Sample Adjustment (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201216900A GB2506147B (en) | 2012-09-21 | 2012-09-21 | Sampling apparatus providing a series of discrete fluid samples in a tube |
| PCT/GB2013/052471 WO2014045053A1 (en) | 2012-09-21 | 2013-09-20 | Fluid sampling apparatus and method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP2897528A1 true EP2897528A1 (en) | 2015-07-29 |
| EP2897528B1 EP2897528B1 (en) | 2022-11-23 |
Family
ID=47190406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP13770962.2A Active EP2897528B1 (en) | 2012-09-21 | 2013-09-20 | Fluid sampling apparatus |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20150238132A1 (en) |
| EP (1) | EP2897528B1 (en) |
| GB (1) | GB2506147B (en) |
| WO (1) | WO2014045053A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110892245A (en) * | 2017-07-21 | 2020-03-17 | 深圳迈瑞生物医疗电子股份有限公司 | Sample analyzer and sampling monitoring method |
| JP6978255B2 (en) * | 2017-08-31 | 2021-12-08 | 日東電工株式会社 | Liquid discharge device and measuring tape |
| CN112362583B (en) * | 2020-09-24 | 2026-01-13 | 孙成章 | Method for quantitative treatment of liquids |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3403957A1 (en) * | 1984-02-04 | 1985-08-08 | Ferring Biotechnik GmbH, 2300 Kiel | DEVICE FOR TAKING BLOOD SAMPLES FOR DIAGNOSIS OF BODY FUNCTIONS |
| CN1030352A (en) * | 1987-07-09 | 1989-01-18 | Avl股份公司 | Measure the method and apparatus of parameters of interest in the live organism |
| US5520817A (en) * | 1994-10-04 | 1996-05-28 | Biologica Co. | Method of fractionating components in liquid chromatography |
| US6130098A (en) * | 1995-09-15 | 2000-10-10 | The Regents Of The University Of Michigan | Moving microdroplets |
| US8251907B2 (en) * | 2005-02-14 | 2012-08-28 | Optiscan Biomedical Corporation | System and method for determining a treatment dose for a patient |
| US20090156975A1 (en) * | 2007-11-30 | 2009-06-18 | Mark Ries Robinson | Robust System and Methods for Blood Access |
| US20100145175A1 (en) * | 2008-08-22 | 2010-06-10 | Soldo Monnett H | Systems and methods for verification of sample integrity |
| US8753290B2 (en) * | 2009-03-27 | 2014-06-17 | Intellectual Inspiration, Llc | Fluid transfer system and method |
| CN101598712A (en) * | 2009-06-30 | 2009-12-09 | 上海华质生物技术有限公司 | Trace distillate collector |
| WO2012177765A2 (en) * | 2011-06-22 | 2012-12-27 | Twin Star Medical, Inc. | System and method for treating compartment syndrome |
-
2012
- 2012-09-21 GB GB201216900A patent/GB2506147B/en active Active
-
2013
- 2013-09-20 WO PCT/GB2013/052471 patent/WO2014045053A1/en not_active Ceased
- 2013-09-20 US US14/429,818 patent/US20150238132A1/en not_active Abandoned
- 2013-09-20 EP EP13770962.2A patent/EP2897528B1/en active Active
-
2017
- 2017-09-01 US US15/693,805 patent/US10835164B2/en active Active
Non-Patent Citations (2)
| Title |
|---|
| None * |
| See also references of WO2014045053A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US10835164B2 (en) | 2020-11-17 |
| EP2897528B1 (en) | 2022-11-23 |
| WO2014045053A9 (en) | 2017-03-23 |
| WO2014045053A1 (en) | 2014-03-27 |
| US20170360344A1 (en) | 2017-12-21 |
| GB2506147A (en) | 2014-03-26 |
| US20150238132A1 (en) | 2015-08-27 |
| GB201216900D0 (en) | 2012-11-07 |
| GB2506147B (en) | 2015-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Henley et al. | Development of an automated blood sampling system for use in humans | |
| US20110266999A1 (en) | Remote Control For Fluid Dispensing Device with a Rechargeable Power Source | |
| RU2758210C2 (en) | System for controlling the course of diabetes with automatic control of basal administration of insulin and manual control of bolus administration of insulin | |
| TWI667629B (en) | A method for operating a diabetes management system | |
| Bhake et al. | Automated 24-hours sampling of subcutaneous tissue free cortisol in humans | |
| JP2024527580A (en) | Wearable non-invasive microneedle sensor | |
| US9119582B2 (en) | Integrated analyte sensor and infusion device and methods therefor | |
| CA2353486C (en) | Glucose monitor calibration methods | |
| US8523797B2 (en) | Automated point-of-care fluid testing device and method of using the same | |
| US10835164B2 (en) | Fluid sampling apparatus and method | |
| US20090312622A1 (en) | Device And Method For Determining A Value Of A Physiological Parameter Of A Body Fluid | |
| CN103932718B (en) | The portable monitoring system of thing is analyzed in dynamic METHOD FOR CONTINUOUS DETERMINATION body fluid | |
| RU2470300C2 (en) | Portable device to measure and control analytes in biological liquids | |
| WO2009060432A1 (en) | Device and method for preventing diabetic complications | |
| WO2013090882A1 (en) | Systems, devices and methods for in situ calibration of implantable sensors | |
| WO2012102889A1 (en) | Hand-held test meter with deep power conservation mode via direct or generated signal application and method for employing such a meter | |
| US11116429B2 (en) | Method for in situ calibration of implantable sensors | |
| US11207463B2 (en) | Apparatuses, systems, and methods for identifying an infusate in a reservoir of an infusion device | |
| WO2012127513A1 (en) | Device for management and sampling of dialysis fluids for use with systems of the cgms type (continuous glucose monitoring systems) and the like | |
| Goddard et al. | Automatic blood sampling equipment for use in studies of animal physiology | |
| US20230173167A1 (en) | Automated drug microinjection pump with wireless communication and method of use | |
| WO2019177938A1 (en) | Intraosseous implantable biological sensor | |
| WO2015051288A1 (en) | Apparatus and method for automated blood analyte monitoring |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20150320 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20200804 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602013082919 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A61B0005145000 Ipc: B01L0003000000 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61B 5/155 20060101ALI20220310BHEP Ipc: A61B 5/15 20060101ALI20220310BHEP Ipc: A61B 5/145 20060101ALI20220310BHEP Ipc: B01L 3/00 20060101AFI20220310BHEP |
|
| INTG | Intention to grant announced |
Effective date: 20220412 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| RBV | Designated contracting states (corrected) |
Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1532810 Country of ref document: AT Kind code of ref document: T Effective date: 20221215 Ref country code: DE Ref legal event code: R096 Ref document number: 602013082919 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20221123 |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1532810 Country of ref document: AT Kind code of ref document: T Effective date: 20221123 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221123 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230323 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230223 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221123 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221123 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221123 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221123 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221123 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221123 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221123 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230323 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221123 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230224 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221123 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221123 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221123 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221123 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221123 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221123 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602013082919 Country of ref document: DE |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221123 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221123 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| 26N | No opposition filed |
Effective date: 20230824 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221123 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230920 |
|
| REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20230930 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230920 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221123 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221123 |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230920 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230930 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230920 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230930 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230930 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221123 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221123 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20130920 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20130920 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20250929 Year of fee payment: 13 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221123 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20250929 Year of fee payment: 13 |